DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for mononeuropathy — screening already-approved drugs against its 31-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMononeuropathy maps to a 31-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for mononeuropathy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
RAB28, member RAS oncogene family (RAB28) — RAB28 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet g3ddrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2HXS · 1.1 Å · ligand GUANOSINE-3'-MONOPHOSPHATE-5'-DIPHOSPHATE (G3D). Experimental structure, not a prediction.
What the evidence adds up to
The 1999 textbook on mononeuropathies was written from frustration at needing multiple sources for a single clinical problem; it covers anatomy, history, examination, electrophysiological findings, differential diagnosis, and causes for each nerve. A 2011 source notes that mononeuropathies are a not uncommon source of pain, listing post-herpetic neuralgia, diabetic mononeuropathy and amyotrophy, mononeuropathy multiplex, entrapment neuropathies, and mononeuropathies due to peripheral nerve tumours as notable painful examples. No treatment outcomes, response rates, or survival data are provided in any of these abstracts.
A 2024 review states that uncommon mononeuropathies are challenging to diagnose because they can mimic joint pathology, radiculopathies, or plexopathies, and because clinicians are unfamiliar with their presentation, anatomy, and less commonly used diagnostic studies. The review recommends careful history, physical examination, and electrodiagnostic evaluation to identify these neuropathies in a timely manner for best treatment, but gives no specific drug, procedure, or numerical outcome. Recent advances in ultrasound and magnetic resonance techniques are said to help confirm clinical suspicion by depicting anatomy and pathology, including findings that mimic mononeuropathy.
No randomised trials, controlled studies, or quantitative efficacy data appear in these abstracts. What is missing is any trial design that tests a specific intervention, any patient stratification by cause or nerve involved, and any funding for such trials. The abstracts offer only diagnostic frameworks and general clinical advice, not evidence for any drug or treatment.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Neurology Neurosurgery & Psychiatry · 1999 · 4 citations · open access
Mononeuropathies: Examination, Diagnosis and Treatment
AbstractMononeuropathies: Examination, Diagnosis and Treatment by a staal, j van gijn, and f spaans (pp 243, £35.00). Published by W B Saunders, London, 1999.
The authors say that they wrote this book from a frustration at having to look at several different sources to solve a single clinical problem.
The introductory chapters contain sound clinical advice on a general approach to patients with mononeuropathy. Then each nerve is dealt with in turn using the same format: anatomy; history; examination—including the method of examination of the relevant muscles and the area of sensory loss—electrophysiological findings; differential diagnosis; causes, often tabulated; and …
AbstractUncommon mononeuropathies are challenging to diagnose as they can mimic joint pathology, radiculopathies, or plexopathies. They are less easily diagnosed due to unfamiliarity with their clinical presentation, knowledge of anatomy, and less commonly used diagnostic studies. A careful history, physical examination, and electrodiagnostic evaluation can help identify these neuropathies in a timely manner to administer the best treatment for resolution of symptoms. Recent advances in ultrasound and magnetic resonance techniques are used to confirm clinical suspicion of peripheral neuropathy by clearly depicting the anatomy and pathology as well as describing findings that mimic mononeuropathy. It is important for neurology, orthopedic, rheumatology, emergency, and primary care physicians to be familiar with less common mononeuropathies.
AbstractMononeuropathies are a not uncommon source of pain, of which, one of the most notable is post-herpetic neuralgia, which is covered in its own section of this book. Other notable painful mononeuropathies include, diabetic mononeuropathy and amyotrophy, mononeuropathy multiplex, entrapment neuropathies, and mononeuropathies due to peripheral nerve tumors.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
